

WHAT IS CLAIMED IS:

1. A method for treating inflammatory bowel disease (IBD) in a mammal comprising administering a therapeutically effective amount of interferon beta in conjunction with factor XIII.
2. The method of claim 1 wherein the factor XIII is recombinant factor XIII.
3. The method of claim 1 wherein the IBD is ulcerative colitis.
4. The method of claim 1 wherein the IBD is Crohn's disease.
5. The method of claim 1 wherein the mammal is further treated with a drug selected from the group consisting of salicylates including sulfasalazine, olsalazine, mesalamine and azulfidine, corticosteroids, immunosuppressants such as azathioprine and 6-mercaptopurine, and antibodies to tumor necrosis factor.
6. The method of claim 1 wherein the interferon beta is interferon beta-1a.
7. The method of claim 1 wherein the interferon beta is interferon beta-1b.
8. The method of claim 1 wherein the mammal is a human.
9. The method of claim 1 wherein the factor XIII is administered at the same time as the interferon beta.
10. The method of claim 1 wherein the factor XIII is administered before the interferon beta.
11. The method of claim 1 wherein the factor XIII is administered after the interferon beta.
12. The method of claim 1 wherein the factor XIII is administered intravenously.

13. The method of claim 1 wherein the factor XIII is administered to or at the lumen.